A nonpsychotropic cannabinoid, HU-211, has cerebroprotective effects after closed head injury in the rat (abst – 1993)http://www.ncbi.nlm.nih.gov/pubmed/8411215
HU-211, a Novel Noncompetitive N-Methyl-D-Aspartate Antagonist, Improves Neurological Deficit and Reduces Infarct Volume After Reversible Focal Cerebral Ischemia in the Rat (full - 1995) http://stroke.ahajournals.org/cgi/co...ull/26/12/2313
45Ca accumulation in rat brain after closed head injury; attenuation by the novel neuroprotective agent HU-211 (abst – 1995)http://www.ncbi.nlm.nih.gov/pubmed/7583233
Development of HU-211 as a neuroprotectant for ischemic brain damage (abst – 1995) http://www.ncbi.nlm.nih.gov/pubmed/7477742
A novel nonpsychotropic cannabinoid, HU-211, in the treatment of experimental pneumococcal meningitis (full - 1996)http://jid.oxfordjournals.org/content/173/3/735.long
HU-211, a nonpsychotropic cannabinoid, produces short- and long-term neuroprotection after optic nerve axotomy (abst – 1996)http://www.ncbi.nlm.nih.gov/pubmed/8714863
Protection Against Septic Shock and Suppression of Tumor Necrosis Factor α and Nitric Oxide Production by Dexanabinol (HU-211), a Nonpsychotropic Cannabinoid (full - 1997) http://jpet.aspetjournals.org/content/283/2/918.full
Cytokine production in the brain following closed head injury: dexanabinol (HU-211) is a novel TNF-alpha inhibitor and an effective neuroprotectant (abst – 1997) http://www.ncbi.nlm.nih.gov/pubmed/9042110
Dexanabinol; a novel neuroprotective drug in experimental focal cerebral ischemia (abst – 1999)http://www.ncbi.nlm.nih.gov/pubmed/10202976
Cannabinoids in clinical practice. (abst - 2000) http://www.ncbi.nlm.nih.gov/pubmed/11152013
Dexanabinol (HU-211) in the treatment of severe closed head injury: a randomized, placebo-controlled, phase II clinical trial (abst - 2002)http://www.ncbi.nlm.nih.gov/pubmed/1...?dopt=Abstract
Dexanabinol: a novel cannabinoid with neuroprotective properties (abst – 2003) http://www.ncbi.nlm.nih.gov/pubmed/14534855
Dexanabinol (HU-211) has a beneficial effect on axonal sprouting and survival after rat optic nerve crush injury (abst – 2003)http://www.ncbi.nlm.nih.gov/pubmed/12535983
Therapeutic potential of cannabinoids in CNS disease (abst – 2003) http://www.ncbi.nlm.nih.gov/pubmed/12617697
Dexanabinol: dexanabinone, HU 211, PA 50211, PRS 211007, sinnabidol (abst - 2003) http://www.ncbi.nlm.nih.gov/pubmed/12757406
Dexanabinol prevents development of vasospasm in the rat femoral artery model (abst – 2008) http://www.ncbi.nlm.nih.gov/pubmed/18256864
Latest Studies Imply That Cannabinoids Are Protective Against Alcohol-Induced Brain Damage (news – 2011)http://networkedblogs.com/mFuuX
Cannabinoid May Treat Brain Cancer (news – 2012) http://www.sciencedaily.com/releases...cience+News%29
Clinical trial evaluates synthetic cannabinoid as brain cancer treatment (news – 2012) http://medicalxpress.com/news/2012-0...oid-brain.html
Cannabinoid May Treat Brain Cancer (news – 2012) http://www.sciencedaily.com/releases...0925142557.htm
Effects of cannabinoids and related fatty acids upon the viability of P19 embryonal carcinoma cells. (abst – 2013)http://www.ncbi.nlm.nih.gov/pubmed/23552853
e-Therapeutics announces continuation of ETS2101 phase I trial in brain cancer (news – 2014) http://www.news-medical.net/news/201...in-cancer.aspx
HU-211, a Novel Noncompetitive N-Methyl-D-Aspartate Antagonist, Improves Neurological Deficit and Reduces Infarct Volume After Reversible Focal Cerebral Ischemia in the Rat (full - 1995) http://stroke.ahajournals.org/cgi/co...ull/26/12/2313
45Ca accumulation in rat brain after closed head injury; attenuation by the novel neuroprotective agent HU-211 (abst – 1995)http://www.ncbi.nlm.nih.gov/pubmed/7583233
Development of HU-211 as a neuroprotectant for ischemic brain damage (abst – 1995) http://www.ncbi.nlm.nih.gov/pubmed/7477742
A novel nonpsychotropic cannabinoid, HU-211, in the treatment of experimental pneumococcal meningitis (full - 1996)http://jid.oxfordjournals.org/content/173/3/735.long
HU-211, a nonpsychotropic cannabinoid, produces short- and long-term neuroprotection after optic nerve axotomy (abst – 1996)http://www.ncbi.nlm.nih.gov/pubmed/8714863
Protection Against Septic Shock and Suppression of Tumor Necrosis Factor α and Nitric Oxide Production by Dexanabinol (HU-211), a Nonpsychotropic Cannabinoid (full - 1997) http://jpet.aspetjournals.org/content/283/2/918.full
Cytokine production in the brain following closed head injury: dexanabinol (HU-211) is a novel TNF-alpha inhibitor and an effective neuroprotectant (abst – 1997) http://www.ncbi.nlm.nih.gov/pubmed/9042110
Dexanabinol; a novel neuroprotective drug in experimental focal cerebral ischemia (abst – 1999)http://www.ncbi.nlm.nih.gov/pubmed/10202976
Cannabinoids in clinical practice. (abst - 2000) http://www.ncbi.nlm.nih.gov/pubmed/11152013
Dexanabinol (HU-211) in the treatment of severe closed head injury: a randomized, placebo-controlled, phase II clinical trial (abst - 2002)http://www.ncbi.nlm.nih.gov/pubmed/1...?dopt=Abstract
Dexanabinol: a novel cannabinoid with neuroprotective properties (abst – 2003) http://www.ncbi.nlm.nih.gov/pubmed/14534855
Dexanabinol (HU-211) has a beneficial effect on axonal sprouting and survival after rat optic nerve crush injury (abst – 2003)http://www.ncbi.nlm.nih.gov/pubmed/12535983
Therapeutic potential of cannabinoids in CNS disease (abst – 2003) http://www.ncbi.nlm.nih.gov/pubmed/12617697
Dexanabinol: dexanabinone, HU 211, PA 50211, PRS 211007, sinnabidol (abst - 2003) http://www.ncbi.nlm.nih.gov/pubmed/12757406
Dexanabinol prevents development of vasospasm in the rat femoral artery model (abst – 2008) http://www.ncbi.nlm.nih.gov/pubmed/18256864
Latest Studies Imply That Cannabinoids Are Protective Against Alcohol-Induced Brain Damage (news – 2011)http://networkedblogs.com/mFuuX
Cannabinoid May Treat Brain Cancer (news – 2012) http://www.sciencedaily.com/releases...cience+News%29
Clinical trial evaluates synthetic cannabinoid as brain cancer treatment (news – 2012) http://medicalxpress.com/news/2012-0...oid-brain.html
Cannabinoid May Treat Brain Cancer (news – 2012) http://www.sciencedaily.com/releases...0925142557.htm
Effects of cannabinoids and related fatty acids upon the viability of P19 embryonal carcinoma cells. (abst – 2013)http://www.ncbi.nlm.nih.gov/pubmed/23552853
e-Therapeutics announces continuation of ETS2101 phase I trial in brain cancer (news – 2014) http://www.news-medical.net/news/201...in-cancer.aspx